https://pittplusme.org/study/2798
Rapid Depression Treatment Study
STUDY BASICS
Do you often feel down, low, or depressed? You may be eligible for a research study to test a new experimental treatment for depression. Over a 45-day period, participants will complete clinical interviews and questionnaires, receive one infusion of drug or placebo, complete a computer-based training treatment, and complete assessments. Compensation provided.
STUDY PURPOSE
Depression is a disabling condition that leads to persistent feelings of sadness and negative thinking, avoidance of important life activities, and negative health consequences. The current study is aimed at investigating a new medication that may have rapid-acting antidepressant effects and a novel, computer-based task designed to retrain the brain and testing whether this changes the way you process information.
COULD THIS STUDY BE RIGHT FOR YOU?
- Age 18-60 years old
- Have tried at least one standard antidepressant medication without success (during the current depressed period)
- No history of bipolar disorder or mania/hypomania
WHAT PARTICIPANTS CAN EXPECT
- An infusion of apimostinel, which may have rapid-acting antidepressant properties, or placebo
- Practice in a computer-based task designed to retrain the brain and create lasting, beneficial changes
IRB: STUDY24010064
- Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose, Parallel Efficacy Study of Apimostinel With or Without Subsequent Automated Self-Association Training in Subjects with Major Depressive Disorder
MEET THE RESEARCHER
Rebecca Price
Rebecca B. Price, PhD, is an Associate Professor of Psychiatry and Psychology at the University of Pittsburgh and director of the Clinical Application of Neuroscience lab. Dr. Price’s research interests center on the role of neurocognitive factors in the etiology, course, and treatment of depression, anxiety, compulsive behaviors, and suicidality. She is particularly interested in the intersection of clinical and neurocognitive research, and translating basic cognitive and affective neuroscience findings into novel brain-based behavioral and biological interventions.